Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a trial of galcanezumab, an antibody to calcitonin gene–related peptide, for the treatment of cluster headache, a subcutaneous dose reduced the mean weekly frequency of cluster attacks from 17.8 to 9.1, as compared with 17.3 to 12.1 in the placebo group. Injection-site reactions occurred in 8% of the patients receiving galcanezumab.
Alternative Titles
Full title
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2256105180
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2256105180
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1813440
